Sanofi seeks to repair ties with Regeneron amid biotech IPO surge

New Sanofi chief executive Belén Garijo has stated that repairing the relationship between her company and development partner Regeneron Pharmaceuticals is now a priority objective for the pharmaceutical giant. During an earnings call held on Thursday, Garijo outlined plans to expand their existing alliance while emphasising the need for greater transparency with the American firm. She noted that Regeneron remains of strategic importance to Sanofi and confirmed that ongoing conversations have already been initiated to identify assets from both sides that would benefit the partnership most effectively.

This announcement comes after Garijo completed her initial assessment since joining the company, a period during which several programmes were discontinued. Among those axed were immune drug prospects including amlitelimab and itepekimab. Looking ahead, Sanofi intends to intensify its business development and mergers and acquisitions activity in preparation for the impending patent cliff affecting top-selling medication Dupixent.

In other corporate developments on Thursday, Bristol Myers Squibb reported second-quarter revenue of $13 billion, a figure that exceeded analyst expectations by 6% compared with the same period last year. The company’s share price fluctuated during trading but ultimately closed at $64.86, representing an increase of 2.8%. While growth was driven partly by newer products such as Reblozyl and Camzyos which saw significant sales increases, legacy blood thinner Eliquis also contributed substantially to the financial performance with sales rising nearly 22%.

However, not all news for Bristol Myers Squibb was positive regarding its pipeline. The firm disclosed slight delays in key studies concerning Cobenfy and an experimental blood thinner known as milvexian. Analysts noted that while these issues were largely anticipated, they introduce uncertainty around the company’s future prospects and temper what might otherwise have been viewed as a strong operational quarter.

Elsewhere in the biotechnology sector, Apnimed successfully raised $192 million through an initial public offering on Thursday, surpassing its projections. The sleep drug developer is backed by Shionogi and represents the 15th IPO for the pharmaceutical industry this year so far. Market data indicates that most recent offerings have been upsized due to high demand leading companies to sell more shares than expected or increase their pricing.

Further market activity saw U.K.-based startup Relation announce a partnership with GSK focused on leveraging artificial intelligence technology to better understand disease biology and uncover new therapeutic targets. Through this collaboration, the two entities will amass data regarding how human cells respond to genetic and drug interventions to guide future medicine development. Relation is set to receive up to $110 million in upfront payments along with milestone fees.

Pfizer also reported positive clinical results for its immune drug Litfulo in late-stage studies involving patients suffering from vitiligo, a skin condition causing depigmentation. The medication demonstrated significant improvements over placebo treatments regarding the severity of patches on the face and skin after 52 weeks. Although Pfizer does not yet sell this specific formulation for alopecia areata where it is already approved, safety profiles remained consistent with previous testing.

In legal news, AbbVie reached settlements that will delay generic versions of Rinvoq until 2037, granting four additional years of exclusivity for a drug generating approximately $6 billion in sales during 2024. Meanwhile, analysis suggests corporate funds including Novo Holdings and Eli Lilly have been among the most active investors in biotech startups this year.

International collaboration continues as Chinese drugmakers formed more than 100 licensing pacts with U.S. and European counterparts since the start of 2025 according to industry data. Additionally, striking study results from last year indicated a new type of medicine may improve upon Merck’s immunotherapy, which has already spurred significant research activity.

The sector remains dynamic as companies navigate patent cliffs, regulatory approvals, and strategic partnerships while investors closely monitor pipeline developments and financial performance across the global pharmaceutical landscape.